Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia

Journal of the Medical Association of Thailand

Volumn 93, Issue 3, 2010, Pages 343-350

  Arunpongpaisal, Suwanna ^a   Srisurapanont, Manit ^b   Kongsakon, Ronnachai ^c   Kitiwattanagul, Khanogwan ^d   Samanwongthai, Umpaikanit ^e  

^a KHON KAEN UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Khon Kaen Univesity   (Thailand)

^e Srithanya Hospital   (Thailand)

Author keywords

Risperidone long acting injection; Schizophrenia; Thai

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; LONG ACTING DRUG; LORAZEPAM; RISPERIDONE;

ADULT; AGGRESSION; AGITATION; ARTICLE; AUDITORY HALLUCINATION; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; INJECTION SITE PAIN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MANCHESTER PSYCHIATRIC RATING SCALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MYALGIA; NAUSEA; PARANOIA; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SHORT FORM 36; SIDE EFFECT; THAILAND; TREATMENT DURATION; VISUAL ANALOG SCALE; VOMITING; WEIGHT GAIN; YALE EXTRAPYRAMIDAL SYMPTOM RATING SCALE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; THAILAND; YOUNG ADULT;

EID: 77951895519     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Branford D. Schizophrenia. In: Walker R, Edwards C, editors. Clinical pharmacy and therapeutics. 3rd ed. London: Churchill Livingstone; 2003: 455-64.
2. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
3. Gardiner-Caldwell Communications. Risperdal ConstaTM product monograph. United Kingdom: Gardiner-Caldwell; 2002: 4-7.
4. Eerdekens M, Fleischhacker WW, Xie Y, Beauclair L, Sauret H, Chrzanowki W, et al. Long-term safety of Long-acting risperidone microspheres. Abstracts of the XIth Biennial Winter Workshop on Schizophrenia. Davos, Switzerland, February 24-March 1, 2002. Schizophr Res 2002; 53: 174.
5. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005; 19: 32-8.
6. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first longacting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32.
7. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250-7.
8. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111-7.
9. Bunditchate A, Saosarn P, Kittiruksanon P, Chuta W. Epidemiology of mental disorders among Thai people. J Psychiatr Assoc Thai 2001; 46: 335-43.
10. Poolsiri N, Sungrussamee P, Lakkonsuwan W, Suppsu C, Prinyanusorn S, Kamolsiripichaiporn P. The study of the problems of medicine taking of the schizophrenic patents in Nakhonratchasima Neuropsychistric Hospital. Bangkok, Thailand: Department of Mental Health, Ministry of Public Health; 1992.
11. Eksuweerapong N, Kasettratat N. Factors affecting medication nonadherence in schizophrenic patients admitted at Suansaranrom Hospital. J Psychiatr Assoc Thai 2007; 52: 412-28.
12. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976: 218-22.
13. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977; 55: 299-308.
14. Kongsakon R, Silpakit C. Thai version of the medical outcome study 36 items short form health survey: an instrument for measuring clinical results in mental disorder patients. Ramathibodi Med J 2000; 23: 8-19.
15. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004; 65: 531-6.
16. Mazure CM, Cellar JS, Bowers MB Jr, Nelson JC, Takeshita J, Zigun B. Assessment of extrapyramidal symptoms during acute neuroleptic treatment. J Clin Psychiatry 1995; 56: 94-100.
17. Ware J, Snow K, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute; 1993.
18. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004; 19: 219-25.
19. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, openlabel study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084-9.
20. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005; 72: 249-58.
21. Ciliberto N, Bossie CA, Urioste R, Lasser RA. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2005; 20: 207-12.
22. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychophar-macol 2004; 19: 241-9.
23. Hay J. Complications at site of injection of depot neuroleptics. BMJ 1995; 311: 421.
24. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001; 62: 855-9.
25. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 2009; 9: 9-31.
26. Moller HJ. Long-acting risperidone: focus on safety. Clin Ther 2006; 28: 633-51.
27. Chue P. Long-acting risperidone injection: efficacy, safety and cost-effectiveness of the first longacting atypical antipsychotic. Neuropsychiatr Dis Treat 2007; 3: 13-39.
28. Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Obenchain RL. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999; 37: 678-91.